5 completed, 1 approved for marketing, 1 terminated. 5 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 4, Terminated 1 |
| Phase 2 | 1 | Completed 1 |
Follow Amifampridine Phosphate: new trials by email Literature Review of Amifampridine Phosphate trials Research Report on Amifampridine Phosphate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Controlled Trial to Evaluate Amifampridine Phosphate in Spinal Muscular Atrophy Type 3 Patients Amifampridine Phosphate, Placebo Oral Tablet - Muscular Atrophy, Spinal | Phase 2 | Completed | Catalyst Pharmaceuticals, Inc. | 13 | 2019-01-21 | 2021-06-01 |
| Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis) Amifampridine Phosphate - Myasthenia Gravis, MuSK, AChR Myasthenia Gravis | Phase 3 | Terminated | Catalyst Pharmaceuticals, Inc. | 63 | 2018-06-11 | 2024-05-07 |
| Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG Amifampridine Phosphate, Placebo Oral Tablet - Myasthenia Gravis, Generalized | Phase 3 | Completed | Catalyst Pharmaceuticals, Inc. | 93 | 2018-04-18 | 2024-03-12 |
| Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS) Amifampridine Phosphate, Placebo Oral Tablet - Lambert-Eaton Myasthenic Syndrome | Phase 3 | Completed | Catalyst Pharmaceuticals, Inc. | 26 | 2016-11-01 | 2018-12-24 |
| Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes amifampridine phosphate, Placebo - Myasthenic Syndromes, Congenital | Phase 3 | Completed | Catalyst Pharmaceuticals, Inc. | 20 | 2016-01-01 | 2021-04-02 |
| A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS) Amifampridine Phosphate, Placebo - Lambert Eaton Myasthenic Syndrome | Phase 3 | Completed | Catalyst Pharmaceuticals, Inc. | 38 | 2011-06-01 | 2018-01-04 |
| Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),Congenital Myasthenic Syndrome Amifampridine Phosphate - Congenital Myasthenic Syndrome, Lambert-Eaton Myasthenic Syndrome | Approved for marketing | Catalyst Pharmaceuticals, Inc. | 2025-03-26 |
Lambert-Eaton Myasthenic Syndrome (3) · Myasthenia Gravis (2) · Myasthenic Syndromes, Congenital (2) · Muscular Atrophy, Spinal (1) · Nystagmus, Pathologic (1)
Catalyst Pharmaceuticals, Inc. (7)
United States (6) · Italy (2) · France (1) · Germany (1) · Hungary (1) · Poland (1) · Russia (1) · Serbia (1) · Spain (1)
Perry Shieh, MD, PhD (2) · Renato Mantegazza, MD (2) · Charles W Gorodetzky, MD, PhD (1) · Lorenzo Maggi, MD (1) · Thomas Crawford, M.D. (1)